DP-C016, a phosphoTau vaccine for the treatment of tauopathies

Head of R&D and Scientific Founder of Déclion Holdings LLC, has been interested in peptide vaccines and immunomodulators for the last 25 years. His previous positions include Head of R&D at Peptimmune Inc., Senior Scientist at Praecis Pharmaceuticals and Cardion AG, and Senior Investigator at Leiden University Medical Center. He completed his postdoctoral training at the Mayo Clinic in Rochester MN in the laboratory of Dr. Chella David, a pioneer in the field of Immunogenetics.